Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

541 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial.
Ahn HK, Sim SH, Suh KJ, Kim MH, Jeong JH, Kim JY, Lee DW, Ahn JH, Chae H, Lee KH, Kim JH, Lee KS, Sohn JH, Choi YL, Im SA, Jung KH, Park YH. Ahn HK, et al. Among authors: choi yl. JAMA Oncol. 2022 Sep 1;8(9):1271-1277. doi: 10.1001/jamaoncol.2022.2310. JAMA Oncol. 2022. PMID: 35797012 Free PMC article. Clinical Trial.
Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery.
Ahn HK, Choi YL, Han JH, Ahn YC, Kim K, Kim J, Shim YM, Um SW, Kim H, Kwon OJ, Sun JM, Ahn JS, Park K, Ahn MJ. Ahn HK, et al. Among authors: choi yl. Lung Cancer. 2013 Mar;79(3):300-6. doi: 10.1016/j.lungcan.2012.11.010. Epub 2012 Dec 21. Lung Cancer. 2013. PMID: 23261144
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.
Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK, Lee KC, Chen M, Kim DW, Kim HK, Min YJ, Kang JH, Choi JH, Kim SW, Zhu G, Wu YL, Kim SR, Lee KH, Song HS, Choi YL, Sun JM, Jung SH, Ahn MJ, Park K. Ahn JS, et al. Among authors: choi jh, choi yl. J Clin Oncol. 2015 Aug 20;33(24):2660-6. doi: 10.1200/JCO.2014.60.0130. Epub 2015 Jul 6. J Clin Oncol. 2015. PMID: 26150444 Clinical Trial.
Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures.
Kan Z, Ding Y, Kim J, Jung HH, Chung W, Lal S, Cho S, Fernandez-Banet J, Lee SK, Kim SW, Lee JE, Choi YL, Deng S, Kim JY, Ahn JS, Sha Y, Mu XJ, Nam JY, Im YH, Lee S, Park WY, Nam SJ, Park YH. Kan Z, et al. Among authors: choi yl. Nat Commun. 2018 Apr 30;9(1):1725. doi: 10.1038/s41467-018-04129-4. Nat Commun. 2018. PMID: 29713003 Free PMC article.
Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.
Kwon MJ, Lee JE, Jeong J, Woo SU, Han J, Kang BI, Kim JE, Moon Y, Lee SB, Lee S, Choi YL, Kwon Y, Song K, Gong G, Shin YK. Kwon MJ, et al. Among authors: choi yl. Front Oncol. 2019 Jul 24;9:667. doi: 10.3389/fonc.2019.00667. eCollection 2019. Front Oncol. 2019. PMID: 31404265 Free PMC article.
541 results